Teleflex Shares Fall After Revised FY22 Outlook Lags Consensus


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


  • Teleflex Incorporated (NYSE:TFX) reported Q2 FY22 revenues of $704.5 million, down 1.3% Y/Y, up 2.3% on a constant currency basis, missing the consensus of $719.50 million.
  • Lower sales from the Interventional Urology segment impacted the revenue. The company did not see the expected operating environment recovery in the Interventional Urology business during the second quarter. 
  • Adjusted diluted EPS increased 1.2% to $3.39, exceeding the consensus of $3.34.
  • The gross margin remained flat at 59%.
  • FY22 Guidance: Teleflex cut GAAP and constant currency revenue growth guidance to (0.45)% to 0.55% and 3.25% to 4.25%, respectively.
  • The company lowered adjusted EPS to $13.00 - $13.40 from $13.70 - $14.30, below the consensus of $13.97.
  • Price Action: TFX shares are down 6.53% at $249.13 during the market session on the last check Thursday.

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving